Search results for "Open-Angle"

showing 10 items of 66 documents

Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.

2019

ObjectivesBimatoprost–timolol (bimatoprost 0.03%–timolol 0.5% fixed-dose combination [FDC]) and tafluprost–timolol (tafluprost 0.0015%–timolol 0.5% FDC) eye drops are currently the only topical intraocular pressure (IOP)-reducing therapies available as preservative-free (PF) prostaglandin and timolol FDC. The aim of this study was to investigate changes to ocular signs and symptoms when patients with ocular hypertension (OH) or open-angle glaucoma (OAG) switched from PF or benzalkonium chloride (BAK)-preserved bimatoprost–timolol to PF tafluprost–timolol eye drops.DesignThis was a 12-week, open-label, phase IV study.SettingSixteen centres in Finland, Germany, Italy and the UK.ParticipantsPa…

MaleIntraocular pressuregenetic structuresOcular hypertensionGlaucomaTimololBenzalkonium chloride0302 clinical medicine1506clinical pharmacology; clinical trials; glaucoma; intraocular pressure; medical ophthalmology; ocular surface; Medicine (all)Aged 80 and overintegumentary systemMedicine (all)General MedicineMiddle AgedIntention to Treat AnalysisDrug Combinations030220 oncology & carcinogenesisTimololFemaleGlaucoma Open-Anglemedicine.drug1718Adultmedicine.medical_specialtyDrug Administration Schedule03 medical and health sciencesOphthalmologymedicineHumansAntihypertensive AgentsIntraocular PressureAgedclinical trialsocular surfaceBimatoprostbusiness.industryResearchPreservatives PharmaceuticalProstaglandins FTafluprostmedicine.diseaseeye diseasesmedical ophthalmologyClinical trialOphthalmologyBimatoprostglaucoma030221 ophthalmology & optometryQuality of LifeOcular Hypertensionsense organsclinical pharmacologyOphthalmic SolutionsbusinessBMJ open
researchProduct

Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.

2010

. Purpose:  The purpose of this study was to investigate the tolerability and intraocular pressure (IOP) reducing effect of the first preservative-free prostaglandin tafluprost (Taflotan®) in patients exhibiting ocular surface side-effects during latanoprost (Xalatan®) treatment. Methods:  A total of 158 patients were enrolled in this open-label multicentre study. Eligible patients had to have at least two ocular symptoms, or one sign and one symptom, during treatment with latanoprost. At baseline, the patients were directly switched from latanoprost to preservative-free tafluprost for 12 weeks. The patients were queried for ocular symptoms, and ocular signs were assessed by using tear brea…

MaleIntraocular pressuregenetic structuresmedicine.medical_treatmentAdministration TopicalMucin 5ACmedicine.disease_causeExfoliation SyndromeConjunctival Diseaseschemistry.chemical_compoundSurveys and QuestionnairesMedicineLatanoprostAged 80 and overBlepharitisGeneral MedicineMiddle AgedTolerabilityPatient SatisfactionAnesthesiaProstaglandins F SyntheticLatanoprostFemalemedicine.symptomIrritationBenzalkonium CompoundsGlaucoma Open-Anglemedicine.drugAdultGonioscopyHyperemiaTonometry OcularHumansBlepharitisAntihypertensive AgentsIntraocular PressureAgedGlaucoma medicationbusiness.industryPreservatives PharmaceuticalProstaglandins FTafluprostHLA-DR Antigensmedicine.diseaseeye diseasesOphthalmoscopyOphthalmologychemistryQuality of LifeItchingOcular Hypertensionsense organsbusinessActa ophthalmologica
researchProduct

European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma

2020

indexation en cours.; PURPOSE: This study investigated the efficacy and safety of a cross-linked collagen stent (XEN 45) with or without cataract surgery in the treatment of glaucoma. SETTING: Real-life setting. DESIGN: Prospective, open-label, multicenter clinical trial. METHODS: Eligible patients with glaucoma inadequately controlled by treatment, or poor compliance or intolerance to topical therapy were included. Patients were divided into those with implant only (solo group; phakic and pseudophakic patients) and implant combined with cataract surgery (combo group). Differences in average intraocular pressure (IOP) and number of medications between baseline and study end (12 months), and…

MaleIntraocular pressuregenetic structuresmedicine.medical_treatmentVisual AcuityGlaucomasurgery0302 clinical medicineLens Implantation IntraocularimplantationProspective StudiesGlaucoma Drainage ImplantsAged 80 and overDry needlingMiddle AgedSensory Systems3. Good healthEuropeTreatment OutcomeFemaleStentsGlaucoma Open-Anglesafetymedicine.medical_specialtyintraocular-pressurepredictive-value03 medical and health sciencesTonometry OcularmedicineHumans[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrganssuccessIntraocular PressureAgedbusiness.industryStentPhacoemulsificationCataract surgerymedicine.diseaseeye diseasesSurgeryClinical trialOphthalmologyphacoemulsification030221 ophthalmology & optometryImplantsense organsbusiness030217 neurology & neurosurgery[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Effect of bicycle ergometer test on intraocular pressure in elderly athletes and controls.

2009

To evaluate the effect of intensive physical exercise on intraocular pressure (IOP) in 66- to 85-year-old subjects IOP was measured before and after a maximal bicycle ergometer test. The non-glaucomatous subjects comprised 85 males and 36 female athletes and 16 male and 22 female controls of corresponding age drawn from a population register. IOP was measured using a non-contact tonometer. The results indicated a decrease (> or = 2 mmHg) in 34% of the subjects, no change in 57% and an increase in 9%. The decrease was more pronounced in subjects with higher pre-test values. In all four subjects with a pre-test value above 22 mmHg a reduction from 4 to 11 mmHg was observed. The change in IOP …

MaleIntraocular pressuremedicine.medical_specialtyAginggenetic structuresPhysical ExertionGlaucomaPhysical exerciseElectrocardiographyRandom AllocationMedicineHumansIntraocular PressureAgedAged 80 and overbiologybusiness.industryAthletesGeneral Medicinemedicine.diseasebiology.organism_classificationeye diseasesTest (assessment)Intensity (physics)OphthalmologyAnesthesiaPhysical therapyExercise TestFemalesense organsBicycle ergometerbusinessPopulation RegisterGlaucoma Open-AngleSportsActa ophthalmologica
researchProduct

Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension

2014

Introduction Fixed-combination intraocular pressure (IOP)—lowering medications simplify treatment regimens for patients requiring 2 ocular hypotensive agents to maintain sufficiently low IOP. The aim of this study was to evaluate the safety and efficacy of fixed-combination brinzolamide 1%/brimonidine 0.2% (BBFC) versus concomitant administration of brinzolamide 1% plus brimonidine 0.2% (BRINZ + BRIM) in patients with open-angle glaucoma or ocular hypertension. Methods This was a prospective, phase 3, multicenter, double-masked, 6-month trial. Patients who had insufficient IOP control with monotherapy or who were receiving 2 IOP-lowering medications were randomized 1:1 to receive twice-dail…

MaleIntraocular pressuremedicine.medical_specialtyConcomitantgenetic structuresIntraocular pressureBrinzolamideThiazinesOcular hypertensionGlaucomaOcular hypertensionlaw.inventionTonometry OcularRandomized controlled trialDouble-Blind MethodlawOphthalmologyQuinoxalinesConcomitant TherapyMedicineHumansPharmacology (medical)Fixed combinationCarbonic anhydrase inhibitorAntihypertensive AgentsOriginal ResearchAgedMedicine(all)Sulfonamidesbusiness.industryBrimonidineAlpha-2 agonistSimbrinza®GlaucomaGeneral MedicineMiddle Agedmedicine.diseaseeye diseasesDysgeusiaOphthalmologyDrug CombinationsTreatment OutcomeBrimonidine TartrateFemalesense organsmedicine.symptombusinessGlaucoma Open-Anglemedicine.drugAdvances in Therapy
researchProduct

Deep sclerectomy versus trabeculectomy with low-dosage mitomycin C: four-year follow-up

2006

<i>Aims:</i> To compare the long-term effects of low-dosage mitomycin C (MMC) in both deep sclerectomy (DSMMC) and trabeculectomy (TPMMC) on intraocular pressure (IOP). <i>Methods:</i> Analysis of extended follow-up of data from a prospective clinical trial. Forty patients were originally randomised to undergo either DSMMC (19 eyes) or TPMMC (21 eyes). Follow-up was performed at postoperative day 1, weeks 1, 2 and 3, as well as months 1, 3, 6, 9, 12, 18, 24, 36 and 48. Two- to three-week data were not included in the statistical analysis. Postoperative complications, number of antiglaucoma medications and IOP were recorded at each visit. Complete (no medications) and…

MaleIntraocular pressuremedicine.medical_specialtygenetic structuresMitomycinmedicine.medical_treatmentEye diseaseGlaucomaKaplan-Meier EstimateExfoliation Syndromelaw.inventionPostoperative ComplicationsRandomized controlled triallawOphthalmologyGlaucoma surgerymedicineHumansTrabeculectomyIntraocular PressureAgedmitomycin CIntraoperative CareDose-Response Relationship Drugbusiness.industrySettore MED/30 - Malattie Apparato VisivoMitomycin Ctrabeculectomydeep sclerectomyclinical trialGeneral MedicineMiddle Agedmedicine.diseaseeye diseasesSensory SystemsSurgeryClinical trialOphthalmologyTreatment OutcomeSclerostomyFemalesense organsbusinessGlaucoma Open-AngleFollow-Up Studies
researchProduct

Patients undergoing long-term treatment with antihypertensive eye drops responded positively with respect to their ocular surface disorder to oral su…

2013

Carmen Galbis-Estrada,1,* Maria D Pinazo-Durán,1,* Jorge Cantú-Dibildox,2 Carla Marco-Ramírez,1 Manuel Díaz-Llópis,1,3 Javier Benítez-del-Castillo21Ophthalmic Research Unit Santiago Grisolia, Department of Surgery/Ophthalmology, Faculty of Medicine, University of Valencia, Valencia, Spain; 2Department of Ophthalmology, Hospital of Jerez, Jerez de la Frontera, Cádiz, Spain; 3University and Polytechnic Hospital La Fe, Valencia, Spain*These authors contributed equally to this workBackground: Glaucoma and dry eye disorders (DEDs) are frequent comorbidities. The antioxidant and anti-inflammatory properties of essential …

MalePathologygenetic structuresPhotophobiadry eye disordersAdministration OralDry Eye SyndromesGlaucomaGastroenterologyAntioxidantschemistry.chemical_compoundMedicineProspective StudiesProspective cohort studyOriginal ResearchAged 80 and overchemistry.chemical_classificationGeneral MedicineMiddle AgedFlow CytometryVascular endothelial growth factorTreatment OutcomeFatty Acids UnsaturatedDry Eye SyndromesFemaleChemokinesmedicine.symptomGlaucoma Open-AnglePolyunsaturated fatty acidAdultmedicine.medical_specialtyessential fatty acidsStatistics NonparametricBlurred visionInternal medicineHumansAntihypertensive AgentsAgedbusiness.industrytearsmedicine.diseasecytokineseye diseasesglaucomachemistryClinical Interventions in AgingDietary SupplementsTearssense organsOphthalmic SolutionsGeriatrics and GerontologybusinessBiomarkersClinical Interventions in Aging
researchProduct

New insights into autoantibody profiles from immune privileged sites in the eye: a glaucoma study.

2011

Glaucoma is a chronic neurodegenerative disease and one of the leading causes of blindness. Autoantibody based immune processes are assumed to be involved in its pathogenesis. However, it is still unclear to what extent autoantibody patterns found in the eye (aqueous humor) are congruent to systemic autoantibodies (blood). Consistency would underline the specificity of known serum antibody markers for glaucoma. In this study we used antigen microarrays to analyze autoantibody reactivities in sera and corresponding aqueous humor samples of primary open-angle glaucoma patients (N=37) and non-glaucomatous controls (N=31). Compared to control subjects several divergent immunoreactivities were i…

MalePathologymedicine.medical_specialtygenetic structuresImmunologyGlaucomaDiseaseCataract ExtractionEyePathogenesisAqueous HumorBehavioral NeuroscienceImmune systemAntigenArtificial IntelligencemedicineHumansAntigensAgedAutoantibodiesbiologyEndocrine and Autonomic Systemsbusiness.industryMicroarray analysis techniquesAutoantibodymedicine.diseaseMicroarray Analysiseye diseasesArea Under CurveImmunoglobulin GImmunologybiology.proteinFemaleOcular Hypertensionsense organsNeural Networks ComputerAntibodybusinessAlgorithmsGlaucoma Open-AngleBrain, behavior, and immunity
researchProduct

Peptides of the variable IgG domain as potential biomarker candidates in primary open-angle glaucoma (POAG)

2017

Autoantibody profiling has gained increasing interest in the research field of glaucoma promising the detection of highly specific and sensitive marker candidates for future diagnostic purposes. Recent studies demonstrated that immune responses are characterized by the expression of congruent or similar complementarity determining regions (CDR) in different individuals and could be used as molecular targets in biomarker discovery. Main objective of this study was to characterize glaucoma-specific peptides from the variable region of sera-derived immunoglobulins using liquid chromatography--mass spectrometry (LC-MS)-based quantitative proteomics. IgG was purified from sera of 13 primary open…

MaleProteomics0301 basic medicineQuantitative proteomicsEnzyme-Linked Immunosorbent AssayComplementarity determining regionProteomics03 medical and health sciencesTandem Mass SpectrometryGeneticsHumansBiomarker discoveryEye ProteinsMolecular BiologyIntraocular PressureGenetics (clinical)Mass screeningAgedAutoantibodiesAged 80 and overbiologyAutoantibodyGeneral MedicineMiddle AgedMolecular biologyFold change030104 developmental biologyImmunoglobulin Gbiology.proteinFemaleAntibodyPeptidesBiomarkersGlaucoma Open-AngleHuman Molecular Genetics
researchProduct

Genome-wide association study for refractive astigmatism reveals genetic co-determination with spherical equivalent refractive error: the CREAM conso…

2015

To identify genetic variants associated with refractive astigmatism in the general population, meta-analyses of genome-wide association studies were performed for: White Europeans aged at least 25 years (20 cohorts, N = 31,968); Asian subjects aged at least 25 years (7 cohorts, N = 9,295); White Europeans aged <25 years (4 cohorts, N = 5,640); and all independent individuals from the above three samples combined with a sample of Chinese subjects aged <25 years (N = 45,931). Participants were classified as cases with refractive astigmatism if the average cylinder power in their two eyes was at least 1.00 diopter and as controls otherwise. Genome-wide association analysis was carried out for …

MaleRefractive errorBLUE MOUNTAINS EYECORNEAL ASTIGMATISMSpherical equivalentGenome-wide association studyastigmatism; gene; SNPDISEASECohort Studies0302 clinical medicineStatisticsGenetics(clinical)Neural Cell Adhesion MoleculesPOPULATIONGenetics (clinical)Original InvestigationGenetics0303 health scienceseducation.field_of_studyAge FactorsHigh Mobility Group ProteinsMiddle Aged3142 Public health care science environmental and occupational health3. Good healthFemaleOPEN-ANGLE GLAUCOMAAdultGenetic MarkersEXPERIMENTALLY-INDUCED MYOPIAKeratoconusSUSCEPTIBILITY LOCICell Adhesion Molecules NeuronaleducationPopulationNerve Tissue ProteinsAstigmatismBiologyWhite People03 medical and health sciencesAGEAsian PeopleMAJOR LOCUSmedicineGeneticsHumans3125 Otorhinolaryngology ophthalmologyeducation030304 developmental biologyGenetic associationCalcium-Binding ProteinsAstigmatismHeritabilitymedicine.diseaseNONCODING RNAS030221 ophthalmology & optometryGenome-Wide Association Study
researchProduct